Literature DB >> 32081469

Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis.

Chrysanthos Grigoratos1, Alberto Aimo2, Claudio Rapezzi3, Dario Genovesi4, Andrea Barison5, Giovanni Donato Aquaro4, Giuseppe Vergaro5, Angela Pucci6, Claudio Passino5, Paolo Marzullo4, Alessia Gimelli4, Michele Emdin5.   

Abstract

BACKGROUND: Planar diphosphonate scintigraphy is an established diagnostic tool for amyloid transthyretin (ATTR) cardiomyopathy. Characterization of the amyloid burden up to the segmental level by single photon emission computed tomography (SPECT) has not been evaluated so far.
METHODS: Data from consecutive patients undergoing cardiac 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP) SPECT and diagnosed with ATTR cardiomyopathy at a tertiary referral center from June 2016 to April 2019 were collected.
RESULTS: Thirty-eight patients were included (median age 81 years, 79% men, 92% with wild-type ATTR). In patients with Perugini score 1, the most intense diphosphonate regional uptake was found in septal segments, particularly in infero-septal segments. Among patients scoring 2, the amyloid burden in the septum became more significant, and extended to inferior and apical segments. Finally, patients scoring 3 displayed an intense and widespread tracer uptake. All patients with Perugini score 1 had LGE in at least one antero-septal, one infero-septal, and one infero-lateral segment. All patients with score 2 displayed LGE in infero-septal, inferior, and infero-lateral segments. LGE became extensive in patients scoring 3, with all patients having at least one LGE-positive segment in each region.
CONCLUSIONS: When assimilating different Perugini grades to evolutive stages of the disease, amyloid deposition seem to progress from the septum to the inferior wall and then to the other regions and from the basis to the apex. The potential of segmental analysis might be particularly relevant in patients with very limited cardiac uptake at planar scintigraphy (Perugini score 1).
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiac magnetic resonance; Diphosphonate; SPECT; Transthyretin amyloidosis

Mesh:

Substances:

Year:  2020        PMID: 32081469     DOI: 10.1016/j.ijcard.2020.02.030

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  New Advanced Imaging Parameters and Biomarkers-A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy.

Authors:  Roxana Cristina Rimbas; Anca Balinisteanu; Stefania Lucia Magda; Simona Ionela Visoiu; Andrea Olivia Ciobanu; Elena Beganu; Alina Ioana Nicula; Dragos Vinereanu
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

Review 2.  99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.

Authors:  Nobuhiro Tahara; Olivier Lairez; Jin Endo; Atsushi Okada; Mitsuharu Ueda; Tomonori Ishii; Yoshinobu Kitano; Hahn-Ey Lee; Eleonora Russo; Toru Kubo
Journal:  ESC Heart Fail       Date:  2021-11-29

3.  Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis.

Authors:  Kouji Ogasawara; Shinya Shiraishi; Noriko Tsuda; Fumi Sakamoto; Seitarou Oda; Seiji Takashio; Kenichi Tsujita; Toshinori Hirai
Journal:  Jpn J Radiol       Date:  2022-01-01       Impact factor: 2.374

Review 4.  Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.

Authors:  Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 5.  Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery.

Authors:  Aldostefano Porcari; Marco Merlo; Claudio Rapezzi; Gianfranco Sinagra
Journal:  Eur J Intern Med       Date:  2020-10-05       Impact factor: 7.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.